BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 24257748)

  • 1. CD4 and BST-2/tetherin proteins retro-translocate from endoplasmic reticulum to cytosol as partially folded and multimeric molecules.
    Petris G; Casini A; Sasset L; Cesaratto F; Bestagno M; Cereseto A; Burrone OR
    J Biol Chem; 2014 Jan; 289(1):1-12. PubMed ID: 24257748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
    Song YE; Cyburt D; Lucas TM; Gregory DA; Lyddon TD; Johnson MC
    Viruses; 2018 Oct; 10(10):. PubMed ID: 30347660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.
    Douglas JL; Viswanathan K; McCarroll MN; Gustin JK; Früh K; Moses AV
    J Virol; 2009 Aug; 83(16):7931-47. PubMed ID: 19515779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes.
    Iwabu Y; Fujita H; Kinomoto M; Kaneko K; Ishizaka Y; Tanaka Y; Sata T; Tokunaga K
    J Biol Chem; 2009 Dec; 284(50):35060-72. PubMed ID: 19837671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vpu downmodulates two distinct targets, tetherin and gibbon ape leukemia virus envelope, through shared features in the Vpu cytoplasmic tail.
    Lucas TM; Janaka SK; Stephens EB; Johnson MC
    PLoS One; 2012; 7(12):e51741. PubMed ID: 23284757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Vpu-Mediated CD4 and Tetherin Downregulation Functions among Major HIV-1 Group M Subtypes.
    Umviligihozo G; Cobarrubias KD; Chandrarathna S; Jin SW; Reddy N; Byakwaga H; Muzoora C; Bwana MB; Lee GQ; Hunt PW; Martin JN; Brumme CJ; Bangsberg DR; Karita E; Allen S; Hunter E; Ndung'u T; Brumme ZL; Brockman MA
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32376625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation.
    Mangeat B; Gers-Huber G; Lehmann M; Zufferey M; Luban J; Piguet V
    PLoS Pathog; 2009 Sep; 5(9):e1000574. PubMed ID: 19730691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polarity changes in the transmembrane domain core of HIV-1 Vpu inhibits its anti-tetherin activity.
    Lv M; Wang J; Wang X; Zuo T; Zhu Y; Kong W; Yu X
    PLoS One; 2011; 6(6):e20890. PubMed ID: 21674066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transmembrane interactions of HIV-1 Vpu and tetherin.
    Guo F; Liang C
    Curr HIV Res; 2012 Jun; 10(4):292-7. PubMed ID: 22524177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction.
    Kueck T; Neil SJ
    PLoS Pathog; 2012; 8(3):e1002609. PubMed ID: 22479182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of HIV-1-host interaction: role of the Vpu accessory protein.
    Dubé M; Bego MG; Paquay C; Cohen ÉA
    Retrovirology; 2010 Dec; 7():114. PubMed ID: 21176220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway.
    Schubert U; Antón LC; Bacík I; Cox JH; Bour S; Bennink JR; Orlowski M; Strebel K; Yewdell JW
    J Virol; 1998 Mar; 72(3):2280-8. PubMed ID: 9499087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ESCRT-0 component HRS is required for HIV-1 Vpu-mediated BST-2/tetherin down-regulation.
    Janvier K; Pelchen-Matthews A; Renaud JB; Caillet M; Marsh M; Berlioz-Torrent C
    PLoS Pathog; 2011 Feb; 7(2):e1001265. PubMed ID: 21304933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β-TrCP dependency of HIV-1 Vpu-induced downregulation of CD4 and BST-2/tetherin.
    Blanchet FP; Mitchell JP; Piguet V
    Curr HIV Res; 2012 Jun; 10(4):307-14. PubMed ID: 22524179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 Vpu and BST-2/tetherin: enemies at the gates.
    Tokunaga K
    Curr HIV Res; 2012 Jun; 10(4):275-6. PubMed ID: 22533470
    [No Abstract]   [Full Text] [Related]  

  • 16. Functional antagonism of rhesus macaque and chimpanzee BST-2 by HIV-1 Vpu is mediated by cytoplasmic domain interactions.
    Yoshida T; Koyanagi Y; Strebel K
    J Virol; 2013 Dec; 87(24):13825-36. PubMed ID: 24109238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of adaptation to human tetherin in HIV-1 group O and P.
    Yang SJ; Lopez LA; Exline CM; Haworth KG; Cannon PM
    Retrovirology; 2011 Sep; 8():78. PubMed ID: 21955466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Purification of eukaryotic tetherin/Vpu proteins and detection of their interaction by ELISA.
    Lv M; Zhu Y; Wang J; Zhang H; Wang X; Zuo T; Liu D; Zhang J; Wu J; Kong W; Yu X
    Protein Expr Purif; 2013 Oct; 91(2):112-8. PubMed ID: 23916489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu.
    Rong L; Zhang J; Lu J; Pan Q; Lorgeoux RP; Aloysius C; Guo F; Liu SL; Wainberg MA; Liang C
    J Virol; 2009 Aug; 83(15):7536-46. PubMed ID: 19474106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sites of action of HIV-1 Vpu in BST-2/tetherin downregulation.
    Arias JF; Iwabu Y; Tokunaga K
    Curr HIV Res; 2012 Jun; 10(4):283-91. PubMed ID: 22524176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.